Obesity Market Summary

• The Obesity Market Size is anticipated to grow with a significant CAGR during the study period (2022-2036).
• The total market size of obesity in the 7MM in 2025 was approximately USD 16 billion, this is anticipated to grow by 2036.
• The Obesity companies developing therapies in the market include - Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma, and others.

Obesity Market and Epidemiology Analysis

• Obesity is recognized as a chronic disease, which is a complex, multifactorial phenotype, affecting, along with overweight, primarily associated with excess adiposity, or body fatness which can manifest metabolically and not just with respect to the size of the body.
• The US FDA has approved XENICAL (orlistat), QSYMIA (phentermine-topiramate), CONTRAVE (naltrexone-bupropion), SAXENDA (liraglutide), WEGOVY (semaglutide), and IMCIVREE (setmelanotide)—for long-term use in overweight and obesity treatment.
• According to DelveInsight’s analysis, the United States represented approximately 60% of the total prevalent obesity cases in 2025 across the 7MM.
• Obesity prevalence for the United States has shown an increasing trend in adult population. As per DelveInsight’s estimates, the total prevalent cases of obesity in the United States was highest for adults (>19 years) and for children (5–19 years), in 2023. These cases are anticipated to increase in both adults and children at moderate CAGR.

Request for unlocking the Sample Page of the "Obesity Market Insights"

Key Factors Driving the Obesity Market

• Rising Disease Burden and Expanding Patient Population: The increasing prevalence of obesity across adults and children in the 7MM is significantly expanding the treatment-eligible population. According to DelveInsight’s analysis, the United States accounted for approximately 60% of total prevalent obesity cases in 2025, while Germany reported the highest prevalence among EU4 and the UK. Growing awareness, sedentary lifestyles, unhealthy dietary patterns, and associated comorbidities such as type 2 diabetes, cardiovascular disorders, and metabolic syndrome continue to drive market growth.
• Rapid Advancements in GLP-1 and Multi-Agonist Therapies: The obesity treatment landscape has transformed with the success of GLP-1 receptor agonists and next-generation incretin-based therapies. The approvals and commercial success of WEGOVY (semaglutide) and ZEPBOUND (tirzepatide) have demonstrated substantial weight reduction and improved metabolic outcomes. Emerging therapies such as Retatrutide, CagriSema, Survodutide, VK2735, Amycretin, and Orforglipron are further strengthening the competitive landscape with enhanced efficacy and differentiated mechanisms of action.
• Strong Clinical Pipeline and Ongoing Innovation: The obesity pipeline remains highly robust, with multiple mid- and late-stage candidates expected to enter the market during the forecast period. Pharmaceutical companies are heavily investing in dual-, triple-, and amylin-based agonists, oral GLP-1 therapies, and combination approaches aimed at improving efficacy, convenience, and long-term adherence. Strategic collaborations, acquisitions, and expanding clinical programs are expected to intensify competition and sustain future market expansion.
• Growing Recognition of Obesity as a Chronic Disease: Obesity is increasingly being recognized as a chronic and multifactorial disease rather than solely a lifestyle condition. This evolving perception has improved physician engagement, encouraged earlier intervention, and increased long-term pharmacological management. KOL perspectives and clinical guidelines are increasingly emphasizing obesity’s strong association with morbidity, mortality, and non-communicable diseases, thereby supporting greater adoption of medical therapies.
• Improving Market Access and Reimbursement Environment: Healthcare systems across the 7MM are gradually evolving to improve access to obesity therapies. Changes in reimbursement frameworks, HTA reforms, Medicare negotiations, and evolving pricing policies across the US, Europe, and Japan are shaping future accessibility. Increased payer interest, government initiatives, and healthcare policy reforms are expected to support broader treatment uptake, although affordability and long-term reimbursement remain key challenges.
  

DelveInsight's “Obesity Market Insights, Epidemiology and Market Forecast – 2036” report delivers an in-depth understanding of obesity, historical and forecasted epidemiology as well as the obesity therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Obesity market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM obesity market size from 2022 to 2036. The report also covers current obesity treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Obesity Disease Understanding

Obesity Overview, Country-Specific Treatment Guidelines and Diagnosis

Obesity is a chronic medical condition characterized by excessive body fat accumulation, which increases the risk of various health issues such as diabetes, cardiovascular diseases, and metabolic disorders. It is primarily measured using the Body Mass Index (BMI), where a BMI of 30 or higher is classified as obese. Obesity results from a combination of genetic, behavioral, environmental, and hormonal factors.

Types of Obesity:

1. Hypothalamic Obesity – Caused by damage to the hypothalamus, leading to impaired hunger regulation and excessive weight gain.

2. Pediatric Obesity – Obesity occurring in children and adolescents, often due to poor diet, lack of physical activity, and genetic factors.

3. HET Obesity/POMC Deficiency Obesity – A rare genetic disorder where mutations in the POMC gene disrupt appetite control, leading to severe early-onset obesity.

4. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity – These conditions result from mutations affecting appetite regulation, causing excessive hunger and severe obesity from an early age.

5. Syndromic and Monogenic Obesity – Rare forms of obesity caused by single-gene mutations or genetic syndromes (e.g., Prader-Willi Syndrome), often accompanied by developmental and metabolic disorders.

Early diagnosis and intervention is the most successful strategy for obesity treatment. Diagnosis of obesity involves proper evaluation of the weight status, which considers many factors and uses various tools and diagnostic tests, including body mass index (BMI), waist circumference measurement, physical exams, and lab tests to check for comorbidities.

The obesity report provides an overview of obesity pathophysiology, diagnostic approaches, and detailed treatment algorithm along with a real-world scenario of a patient’s journey beginning from the first symptom, the time taken for diagnosis to the entire treatment process.

Also, Read @ XENICAL Drug Insight

Further details related to country-based variations in diagnosis are provided in the report...

Obesity Treatment

The management of obesity and its associated comorbidities has blown over time. The current treatment of obesity aims to reduce body weight and body fat percentage to prevent the onset of obesity-related health problems and improve the overall health condition of the patient. In the last century, the pharmacological management of obesity has included amphetamines, thyroid hormones, dinitrophenol and various drug combinations (rainbow pills) that were withdrawn shortly after regulatory approval due to serious adverse effect.

Approved treatments for obesity particularly pharmacotherapy mostly remain underutilized. The reasons underlying the low uptake of medical therapy for obesity are complex, ranging from practical issues of insurance coverage and cost to concerns about safety and efficacy, as well as continued disease-related stigma, even among providers. The weight-loss medications that are approved by the US FDA include, CONTRAVE (naltrexone-bupropion), SAXENDA (liraglutide), XENICAL (orlistat), QSYMIA (phentermine-topiramate), WEGOVY (semaglutide), IMCIVREE (setmelanotide), and others.

Know More @ QSYMIA Drug Insight

Further details related to country-based variations in treatment are provided in the report...

Obesity Epidemiology

The obesity epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The obesity epidemiology is segmented with detailed insights into Total Prevalent Cases of Obesity, Total Obesity Patients Seeking Help, and Total Treated Cases of Obesity.

Key Findings from Obesity Epidemiological Analysis and Forecast

• According to DelveInsight’s analysis, the United States represented approximately 60% of the total prevalent obesity cases in 2025 across the 7MM.
• In 2025, around 5.5 million children (5–19 years) in the US were reported to be living with obesity. 
• In 2025, Germany reported the highest number of prevalent obesity cases among EU4 and the UK, with approximately 18 million cases. 
• The number of treated obesity cases in Japan has been steadily increasing, with approximately 150,000 treated adult cases and approximately 180 treated children cases in 2025. 
• As per CDC estimates cited in the PPT, in the US, 1 in 5 children and 2 in 5 adults have obesity.

Obesity Epidemiology Segmentation

• Total Prevalent Cases of Obesity in the 7MM
• Total Obesity Patients Seeking Help in the 7MM
• Total Treated Cases of Obesity in the 7MM

Obesity Recent Developments in the Treatment Landscape

• In April 2026, Eli Lilly and Company announced that FOUNDAYO (orforglipron) is now available for adults with obesity or overweight and related comorbidities following its US FDA approval on April 1, 2026.
• In January 2026, Novo Nordisk announced that the WEGOVY pill, the first and only oral GLP-1 therapy approved for weight loss in adults, became widely available across the United States. 
• In December 2025, Novo Nordisk submitted a New Drug Application (NDA) to the US FDA for once-weekly CagriSema injection for long-term weight management in adults with obesity or overweight.
• In September 2025, Regeneron reported interim Phase II COURAGE trial results showing that combining semaglutide with trevogrumab, with or without garetosmab, helped preserve lean mass and enhance fat loss in obesity treatment. 
• In September 2025, Eli Lilly’s oral GLP-1 therapy orforglipron demonstrated significant weight loss and cardiometabolic benefits in the ATTAIN-1 study published in The New England Journal of Medicine.

Obesity Drug Analysis

The drug chapter segment of the obesity report encloses a detailed analysis of obesity marketed drugs and late-stage (Phase III and Phase II) Obesity pipeline drugs. It also deep dives into the obesity pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Marketed Obesity Drugs

IMCIVREE (setmelanotide): Rhythm Pharmaceuticals

Imcivree is a melanocortin 4 (MC4) receptor agonist indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity. In November 2020, Rhythm Pharmaceuticals announced the US FDA approval of Imcivree as the first-ever therapy for chronic weight management in patients with obesity due to POMC, PCSK1, or LEPR deficiency. Earlier, in May 2017, FDA expanded the Breakthrough Therapy Designation to disorders involving genetic defects upstream of the melanocortin-4 receptor in the leptin-melanocortin pathway.

ZEPBOUND (tirzepatide): Eli Lilly and Company

Tirzepatide is a once-weekly glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. In November 2023, the US FDA approved Eli Lilly and Company's ZEPBOUND (tirzepatide) injection, the first obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors. ZEPBOUND is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and also have weight-related medical problems such as hypertension, dyslipidemia, Type II diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off.

You may read this @ CONTRAVE Drug Insight

Note: Detailed marketed therapies assessment will be provided in the final report...

Emerging Obesity Drugs

Survodutide (BI 456906): Boehringer Ingelheim

Boehringer Ingelheim is developing BI 456906, a dual GLP-1/glucagon receptor agonist for obesity, overweight, and Metabolic dysfunction-associated steatohepatitis. Based on oxyntomodulin, it is designed to regulate metabolism through dual receptor activation in patients with BMI ≥27 and related metabolic conditions. The therapy is currently in Phase III clinical development within the company’s cardiometabolic pipeline.

RGT-075: Regor Therapeutics

RGT-075 is an orally bioavailable, once-daily, small molecule GLP-1R full agonist discovered and developed by Regor for the treatment of metabolic diseases, such as type-2 diabetes mellitus and obesity or overweight with weight-related comorbidities. Regor previously completed Phase IIa studies in patients with obesity, Phase I single ascending dose (SAD) in healthy volunteers and multiple ascending dose (MAD) in patients with diabetes. RGT-075 was safe and well-tolerated in clinical trials completed to date, with emerging efficacies comparable to the approved peptide GLP-1 drugs. 

Read More @ SAXENDA Drug Insight

Note: Detailed emerging therapies assessment will be provided in the final report...

Obesity Market Outlook

Key players, such as Novo Nordisk, Boehringer Ingelhium, and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of obesity.

• The total market size of obesity in the 7MM in 2025 was approximately USD 16 billion, this is anticipated to grow by 2036.
• Recent years have witnessed remarkable advancements in the understanding of obesity’s emerging drug targets, significantly expanding the landscape of treatment possibilities. Researchers are increasingly focused on identifying novel targets for drug development, with the aim of creating pharmacological treatments that are not only more effective but also more precise in addressing the multifaceted nature of obesity. 
• The US accounted for the largest market size of obesity in 2025, i.e. nearly 85% in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan.

Obesity Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2024–2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Know More @ WEGOVY Drug Insight

Further detailed analysis of emerging therapies drug uptake in the report...

Obesity Clinical Trial Activities

The Obesity pipeline report provides insights into different Obesity clinical trials within Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

Obesity Pipeline Development Activities

The Obesity clinical trials analysis report covers information on collaborations, acquisitions and mergers, licensing, and patent details for obesity emerging therapies.

Latest KOL Views on Obesity Market Report

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 20+ KOLs in the 7MM. Centers such as Harvard Medical School, World Obesity Federation, Showa University, etc., were contacted. Their opinion helps understand and validate current and emerging treatment patterns of obesity. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Obesity Report Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. In efficacy, the trial’s primary and secondary outcome measures are evaluated.

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Get More Details @ IMCIVREE Drug Insight

Obesity Market Access and Reimbursement

Reimbursement of rare disease therapies can be limited due to lack of supporting policies and funding, challenges of high prices, lack of specific approaches to evaluating rare disease drugs given limited evidence, and payers’ concerns about budget impact. The high cost of rare disease drugs usually has a limited effect on the budget due to the small number of eligible patients being prescribed the drug. The US FDA has approved several rare disease therapies in recent years. From a patient perspective, health insurance and payer coverage guidelines surrounding rare disease treatments restrict broad access to these treatments, leaving only a small number of patients who can bypass insurance and pay for products independently.

The Obesity market report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Obesity Market Report

• The Obesity market report covers a segment of key events, an executive summary, descriptive overview of obesity, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country specific treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging Obesity therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the obesity market, historical and forecasted Obesity market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Obesity market report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM obesity market.

Obesity Market Report Insights

• Obesity Patient Population
• Obesity Therapeutic Approaches
• Obesity Pipeline Analysis
• Obesity Market Size
• Obesity Market Trends
• Existing and Future Obesity Market Opportunity

Obesity Market Report Key Strengths

• Eleven-year Forecast
• 7MM Coverage
• Obesity Epidemiology Segmentation
• Inclusion of Country Specific Treatment Guidelines
• KOL’s Feedback On Approved and Emerging Obesity Therapies
• Key Cross Competition
• Conjoint Analysis
• Obesity Drugs Uptake
• Key Obesity Market Forecast Assumptions

Obesity Market Report Assessment

• Current Obesity Treatment Practices
• Obesity Unmet Needs
• Obesity Pipeline Product Profiles
• Obesity Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Obesity Market Drivers
• Obesity Market Barriers

FAQs Related to Obesity Market Report:

• What is the growth rate of the 7MM obesity treatment market?
• What was the total Obesity market size, the market size by therapies, market share (%) distribution in 2022, and what would it look like in 2036? What are the contributing factors/key catalysts for this growth?
• Is there any unexplored patient setting that can open the window for growth in the future?
• What are the pricing variations among different geographies for approved and off-label Obesity therapies?
• How would the Obesity market drivers, barriers, and future opportunities affect the Obesity market dynamics and subsequent analysis of the associated trends?
• What are the current and emerging options for the treatment of obesity?
• How many companies are developing therapies for the treatment of obesity?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing Obesity therapies?
• Patient/physician acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved Obesity therapies?

Reasons to buy Obesity Market Forecast Report

• The Obesity market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the obesity market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing Obesity market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the Obesity market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging Obesity therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Obesity market so that the upcoming players can strengthen their development and launch strategy.

Unlock a Wealth of Insights with Related Articles, Video, and Infographics:- 

• Obesity: A Worldwide Pandemic with Advancing Management Options
• Obesity Treatment: Which Pipeline Therapy Will Revolutionize the Therapeutics Segment?
• The Obesity Pandemic: What can we do about it?
• Obesity Treatment Market: Infographics
• Obesity Market: Video

Stay Updated with Us @ Latest DelveInsight Blog